
  
    
      
        Diabetes_NNP :_: Epidemiology_NNP and_CC Complications_NNP
        Treatment_NNP for_IN ,_, and_CC the_DT prognosis_NN of_IN ,_, type-_NN 1_CD diabetes_NN mellitus_JJ (_( T_NN 1_CD DM_NNP )_) has_VBZ progressed_VBN
        dramatically_RB during_IN the_DT last_JJ century_NN ,_, but_CC the_DT disease_NN remains_VBZ a_DT major_JJ cause_NN of_IN morbidity_NN
        and_CC mortality_NN ._. Although_IN precise_JJ figures_NNS are_VBP not_RB available_JJ ,_, over_IN 1_CD million_CD United_NNP States_NNPS
        citizens_NNS currently_RB live_VBP with_IN the_DT disease_NN ,_, with_IN approximately_RB 30_CD ,_, 000_CD new_JJ cases_NNS diagnosed_VBN in_IN
        the_DT US_NNP each_DT year_NN ._. The_DT total_JJ number_NN of_IN people_NNS with_IN diabetes_NN worldwide_NN is_VBZ expected_VBN to_TO rise_VB to_TO
        366_CD million_CD in_IN 2030_CD ,_, up_RB from_IN 171_CD million_CD in_IN 2000_CD [_NN 1_CD ]_NN ._.
        The_DT exact_JJ etiology_NN of_IN the_DT disease_NN remains_VBZ uncertain_JJ ,_, but_CC extensive_JJ research_NN suggests_VBZ an_DT
        interaction_NN between_IN genetic_JJ predisposition_NN and_CC environment_NN ._. In_IN fact_NN ,_, for_IN unknown_JJ reasons_NNS ,_,
        the_DT incidence_NN of_IN T_NN 1_CD DM_NNP is_VBZ increasing_VBG [_NN 2_CD ]_NN ._. Diabetes_NNP continues_VBZ to_TO have_VB a_DT tremendous_JJ societal_NN
        impact_NN ;_: it_PRP is_VBZ both_DT difficult_JJ and_CC expensive_JJ to_TO treat_VB and_CC is_VBZ associated_VBN with_IN a_DT number_NN of_IN
        long-term_JJ complications_NNS ,_, including_VBG kidney_NN failure_NN ,_, blindness_NN ,_, nerve_NN damage_NN ,_, and_CC premature_JJ
        mortality_NN (_( predominately_RB due_JJ to_TO cardiovascular_JJ problems_NNS )_) ._.
      
      
        Insulin_NNP 's_POS Impact_NNP
        Banting_NNP and_CC Best_JJS 's_POS discovery_NN of_IN insulin_NN in_IN the_DT early_JJ 1920_CD s_VBZ revolutionized_VBD diabetes_NN
        treatment_NN and_CC greatly_RB improved_VBD the_DT prognosis_NN for_IN what_WP had_VBD previously_RB been_VBN a_DT rapidly_RB fatal_JJ
        disease_NN ._. As_IN shown_VBN by_IN the_DT Diabetes_NNP Control_NNP and_CC Complications_NNP Trial_NNP and_CC the_DT more_RBR recent_JJ
        Epidemiology_NNP of_IN Diabetes_NNP Interventions_NNP and_CC Complications_NNP trial_NN ,_, insulin_NN therapy_NN has_VBZ made_VBN
        such_JJ considerable_JJ advances_NNS (_( with_IN better_JJR insulin_NN formulations_NNS and_CC delivery_NN systems_NNS )_) that_IN
        many_JJ patients_NNS can_MD maintain_VB their_PRP$ blood_NN sugar_NN levels_NNS within_IN a_DT tight_JJ range_NN and_CC thereby_RB reduce_VB
        their_PRP$ risk_NN for_IN the_DT disease_NN 's_POS long-term_JJ complications_NNS [_NN 3_CD ,_, 4_CD ,_, 5_CD ]_NN ._. In_IN addition_NN ,_, improved_VBN
        treatment_NN of_IN other_JJ associated_VBN conditions_NNS such_JJ as_IN hypertension_NN and_CC hyperlipidemia_NN have_VBP
        helped_VBN reduce_VB ,_, or_CC at_IN least_JJS delay_NN ,_, many_JJ of_IN the_DT long-term_JJ sequelae_NN of_IN diabetes_NN [_NN 6_CD ]_NN ._. However_RB ,_,
        problems_NNS with_IN insulin-based_JJ treatment_NN regimens_NNS persist_VBP ._. For_IN the_DT patient_NN ,_, treatment_NN is_VBZ
        expensive_JJ and_CC difficult_JJ ,_, requiring_VBG strict_JJ attention_NN to_TO blood_NN glucose_NN monitoring_NN ,_, insulin_NN
        dosing_VBG ,_, diet_NN ,_, and_CC exercise_NN ._. Further_RB ,_, good_JJ glycemia_NN control_NN is_VBZ not_RB easily_RB achieved_VBN by_IN all_DT
        patients_NNS ,_, and_CC even_RB for_IN those_DT able_JJ to_TO achieve_VB this_DT goal_NN ,_, the_DT treatment_NN is_VBZ not_RB always_RB
        completely_RB effective_JJ ._.
      
      
        Promising_NNP Directions_NNP
        Just_RB as_IN financial_JJ investors_NNS balance_NN a_DT portfolio_NN ,_, with_IN some_DT risky_JJ investments_NNS and_CC others_NNS
        that_WDT are_VBP more_JJR secure_VB ,_, researchers_NNS will_MD undoubtedly_RB continue_VB to_TO further_VB refine_VB “ secure_VB”
        insulin-based_JJ regimens_NNS to_TO help_VB patients_NNS achieve_VB even_RB better_JJR glycemia_NN control_NN ._. At_IN the_DT same_JJ
        time_NN ,_, scientists_NNS are_VBP pursuing_VBG more_RBR high-risk_JJ ,_, high-payoff_JJ approaches_NNS to_TO revolutionize_VB
        diabetes_NN care_NN ._. One_CD such_JJ approach_NN is_VBZ the_DT closed-loop_JJ insulin_NN pump_NN (_( i_NNP ._. e_SYM ._. ,_, a_DT pump_NN that_WDT
        continuously_RB monitors_VBZ blood_NN glucose_NN and_CC concurrently_RB converts_VBZ that_IN data_NNS into_IN appropriate_JJ
        insulin_NN dosing_VBG )_) ,_, which_WDT offers_VBZ the_DT potential_NN to_TO serve_VB as_IN a_DT mechanical_JJ pancreas_NN ._. However_RB ,_,
        such_JJ a_DT mechanical_JJ system_NN would_MD need_VB be_VB fail-safe_JJ in_IN order_NN to_TO avoid_VB devastating_JJ effects_NNS
        (_( e_SYM ._. g_SYM ._. ,_, if_IN the_DT monitor_NN were_VBD to_TO register_VB a_DT falsely_RB elevated_VBD blood_NN glucose_NN and_CC thereby_RB trigger_VB
        an_DT inappropriately_RB high_JJ insulin_NN dose_NN )_) ._. In_IN other_JJ ,_, similar_JJ scenarios_NNS with_IN no_DT tolerance_NN for_IN
        error_NN ,_, NASA_NNP (_( for_IN instance_NN )_) sets_NNS up_RP systems_NNS in_IN which_WDT two_CD independent_JJ monitoring_NN systems_NNS must_MD
        come_VB up_RB with_IN similar_JJ measurements_NNS before_IN an_DT action_NN is_VBZ taken_VBN ._. Perhaps_RB the_DT engineering_NN
        obstacles_NNS that_WDT currently_RB limit_NN the_DT closed-loop_JJ insulin_NN pump_NN can_MD be_VB overcome_VBN ._.
        Other_JJ research_NN groups_NNS are_VBP investigating_VBG whether_IN the_DT insulin-producing_JJ cells_NNS within_IN the_DT
        pancreas_NN (_( so-called_JJ ß_NN cells_NNS )_) ,_, might_MD be_VB promoted_VBN to_TO regenerate_VB (_( in_IN vitro_NN or_CC in_IN vivo_NN )_) to_TO
        replace_VB the_DT pool_NN of_IN insulin-producing_JJ cells_NNS reduced_VBN by_IN autoimmune_JJ destruction_NN ._. Another_DT
        promising_JJ approach_NN for_IN creating_VBG cells_NNS capable_JJ of_IN physiologically_RB regulated_VBN insulin_NN
        secretion_NN is_VBZ to_TO “ coax_VB” stem_VB cells—undifferentiated_JJ cells_NNS with_IN self-regenerative_JJ capacity—to_NN
        differentiate_VB into_IN ß-like_JJ cells_NNS ._. Gene_NNP therapy_NN approaches_NNS may_MD overcome_VB present_JJ obstacles_NNS and_CC
        result_NN in_IN cells_NNS capable_JJ of_IN physiologically_RB regulated_VBN insulin_NN secretion_NN [_NN 7_CD ]_NN ._. Lastly_NNP ,_, the_DT
        recent_JJ completion_NN of_IN the_DT Human_NNP Genome_NNP Project_NNP suggests_VBZ that_IN the_DT genetics_NNS of_IN diabetes_NN may_MD
        eventually_RB become_VB clearer_JJR and_CC may_MD direct_VB appropriate_JJ preventative_JJ approaches_NNS ._.
        While_IN such_JJ potential_JJ therapies_NNS remain_VBP experimental_JJ ,_, pancreas_NN transplantation_NN is_VBZ
        currently_RB performed_VBN in_IN patients_NNS with_IN complicated_VBN diabetes_NN ._. However_RB ,_, a_DT recent_JJ report_NN that_WDT
        shows_VBZ benefit_NN for_IN patients_NNS with_IN both_DT diabetes_NN and_CC kidney_NN failure_NN who_WP receive_VBP a_DT combined_VBN
        pancreas_NN and_CC kidney_NN transplant_NN also_RB found_VBD that_IN an_DT isolated_VBN pancreas_NN transplant_NN (_( for_IN
        patients_NNS with_IN preserved_VBN kidney_NN function_NN )_) actually_RB worsened_VBN survival_NN [_NN 8_CD ]_NN ._. The_DT main_JJ point_NN is_VBZ
        that_IN as_IN we_PRP develop_VBP new_JJ therapies_NNS ,_, we_PRP must_MD maintain_VB humility_NN and_CC recognize_VB that_IN newer_JJR
        approaches_NNS may_MD have_VB great_JJ promise_NN ,_, but_CC they_PRP also_RB have_VBP the_DT potential_NN for_IN harm_NN ._.
      
      
        History_NN of_IN Islet_NNP Transplantation_NNP
        Islet_NNP transplantation_NN has_VBZ recently_RB received_VBN considerable_JJ interest_NN as_IN a_DT potentially_RB
        definitive_JJ treatment_NN for_IN diabetes_NN ._. The_DT concept_NN of_IN islet_NN transplantation_NN is_VBZ not_RB
        new—investigators_NNS as_RB early_RB as_IN the_DT English_NNP surgeon_NN Charles_NNP Pybus_NNP (_( 1882_CD –_NN 1975_CD )_) attempted_VBD to_TO
        graft_NN pancreatic_JJ tissue_NN to_TO cure_VB diabetes_NN ._. Most_JJS ,_, however_RB ,_, credit_NN the_DT recent_JJ era_NN of_IN islet_NN
        transplantation_NN research_NN to_TO Paul_NNP Lacy_NNP 's_POS studies_NNS dating_VBG back_RB more_JJR than_IN three_CD decades_NNS ._. In_IN
        1967_CD ,_, Lacy_NNP 's_POS group_NN described_VBD a_DT novel_NN collagenase-based_JJ method_NN (_( later_RB modified_VBN by_IN Dr_NNP ._.
        Camillo_NNP Ricordi_NNP ,_, then_RB working_VBG with_IN Dr_NNP ._. Lacy_NNP )_) to_TO isolate_VB islets_NNS ,_, paving_VBG the_DT way_NN for_IN future_NN
        in_IN vitro_NN and_CC in_IN vivo_NN islet_NN experiments_NNS [_NN 9_CD ]_NN ._. Subsequent_JJ studies_NNS showed_VBD that_WDT transplanted_VBN
        islets_NNS could_MD reverse_VB diabetes_NN in_IN both_DT rodents_NNS and_CC non-human_JJ primates_NNS [_NN 10_CD ,_, 11_CD ]_NN (_( Figure_NN 1_LS )_) ._. In_IN
        a_DT summary_NN of_IN the_DT 1977_CD Workshop_NNP on_IN Pancreatic_NNP Islet_NNP Cell_NNP Transplantation_NNP in_IN Diabetes_NNP ,_, Lacy_NNP
        commented_VBD on_IN the_DT feasibility_NN of_IN “ islet_NN cell_NN transplantation_NN as_IN a_DT therapeutic_JJ approach_NN [_NN for_IN ]_NN
        the_DT possible_JJ prevention_NN of_IN the_DT complications_NNS of_IN diabetes_NN in_IN man_NN” [_NN 12_CD ]_NN ._. Improvements_NNP in_IN
        isolation_NN techniques_NNS and_CC immunosuppressive_JJ regimens_NNS ushered_VBD in_IN the_DT first_JJ human_JJ islet_NN
        transplantation_NN clinical_JJ trails_NNS in_IN the_DT mid-_NN 1980_CD s_VBZ ._. Yet_RB despite_IN continued_VBD procedural_JJ
        improvements_NNS ,_, only_RB about_IN 10_CD %_NN of_IN islet_NN recipients_NNS in_IN the_DT late_JJ 1990_CD s_VBZ achieved_VBN euglycemia_NN
        (_( normal_JJ blood_NN glucose_NN )_) ._. In_IN 2000_CD ,_, Dr_NNP ._. James_NNP Shapiro_NNP and_CC colleagues_NNS published_VBD a_DT report_NN
        describing_VBG seven_CD consecutive_JJ patients_NNS who_WP achieved_VBD euglycemia_NN following_VBG islet_NN
        transplantation_NN using_VBG a_DT steroid-free_JJ protocol_NN and_CC large_JJ numbers_NNS of_IN donor_NN islets_NNS ,_, since_IN
        referred_VBD to_TO as_IN the_DT Edmonton_NNP protocol_NN [_NN 13_CD ]_NN ._. This_DT protocol_NN has_VBZ been_VBN adapted_VBN by_IN islet_NN
        transplant_NN centers_NNS around_IN the_DT world_NN and_CC has_VBZ greatly_RB increased_VBN islet_NN transplant_NN success_NN ._.
      
      
        Current_NNP Limitations_NNPS of_IN Islet_NNP Transplantation_NNP
        While_IN significant_JJ progress_NN has_VBZ been_VBN made_VBN in_IN the_DT islet_NN transplantation_NN field_NN [_NN 14_CD ]_NN ,_, many_JJ
        obstacles_NNS remain_VBP that_IN currently_RB preclude_VB its_PRP$ widespread_JJ application_NN ._. Two_CD of_IN the_DT most_RBS
        important_JJ limitations_NNS are_VBP the_DT currently_RB inadequate_JJ means_NNS for_IN preventing_VBG islet_NN rejection_NN ,_,
        and_CC the_DT limited_JJ supply_NN of_IN islets_NNS for_IN transplantation_NN ._. Current_JJ immunosuppressive_JJ regimens_NNS
        are_VBP capable_JJ of_IN preventing_VBG islet_NN failure_NN for_IN months_NNS to_TO years_NNS ,_, but_CC the_DT agents_NNS used_VBN in_IN these_DT
        treatments_NNS are_VBP expensive_JJ and_CC may_MD increase_VB the_DT risk_NN for_IN specific_JJ malignancies_NNS and_CC
        opportunistic_JJ infections_NNS ._. In_IN addition_NN ,_, and_CC somewhat_RB ironically_RB ,_, the_DT most_RBS commonly_RB used_VBN
        agents_NNS (_( like_IN steroids_NNS ,_, calcineurin_NN inhibitors_NNS ,_, and_CC rapamycin_NN )_) are_VBP also_RB known_VBN to_TO impair_VB
        normal_JJ islet_NN function_NN and_CC /_NN or_CC insulin_NN action_NN ._. Further_RB ,_, like_IN all_DT medications_NNS ,_, the_DT agents_NNS have_VBP
        other_JJ associated_VBN toxicities_NNS ,_, with_IN side_NN effects_NNS such_JJ as_IN oral_JJ ulcers_NNS ,_, peripheral_JJ edema_NN ,_,
        anemia_NN ,_, weight_NN loss_NN ,_, hypertension_NN ,_, hyperlipidemia_NN ,_, diarrhea_NN ,_, and_CC fatigue_NN [_NN 15_CD ]_NN ._. Perhaps_RB of_IN
        greatest_JJS concern_NN to_TO the_DT patient_NN and_CC physician_NN is_VBZ the_DT harmful_JJ effect_NN of_IN certain_JJ widely_RB
        employed_VBN immunosuppressive_JJ agents_NNS on_IN renal_JJ function_NN ._. For_IN the_DT patient_NN with_IN diabetes_NN ,_, renal_JJ
        function_NN is_VBZ a_DT crucial_JJ factor_NN in_IN determining_VBG long-term_JJ outcome_NN ,_, and_CC calcineurin_NN inhibitors_NNS
        (_( tacrolimus_JJ and_CC cyclosporin_NN )_) are_VBP significantly_RB nephrotoxic_JJ ._. Thus_RB ,_, while_IN some_DT patients_NNS with_IN
        a_DT pancreas_NN transplant_NN tolerate_VB the_DT immunosuppressive_JJ agents_NNS well_RB ,_, and_CC for_IN such_JJ patients_NNS
        diabetic_JJ nephropathy_NN can_MD gradually_RB improve_VB ,_, in_IN other_JJ patients_NNS the_DT net_JJ effect_NN (_( decreased_VBD
        risk_NN due_JJ to_TO the_DT improved_VBN blood_NN glucose_NN control_NN ,_, increased_VBN risk_NN from_IN the_DT immunosuppressive_JJ
        agents_NNS )_) may_MD worsen_VB kidney_NN function_NN ._. Indeed_RB ,_, Ojo_NNP et_CC al_NN ._. have_VBP published_VBN an_DT analysis_NN
        indicating_VBG that_IN among_IN patients_NNS receiving_VBG other-than-kidney_JJ allografts_NNS ,_, 7_CD %_NN –_NN 21_CD %_NN end_NN up_RB with_IN
        renal_JJ failure_NN as_IN a_DT result_NN of_IN the_DT transplant_NN and_CC /_NN or_CC subsequent_JJ immunosuppression_NN [_NN 16_CD ]_NN ._.
        Looked_NNP at_IN another_DT way_NN ,_, patients_NNS with_IN heart_NN ,_, liver_NN ,_, lung_NN ,_, or_CC kidney_NN failure_NN have_VBP a_DT dismal_JJ
        prognosis_NN for_IN survival_NN ,_, so_IN the_DT toxicity_NN associated_VBN with_IN immunosuppression_NN is_VBZ warranted_VBN (_( the_DT
        benefits_NNS of_IN graft_NN survival_NN outweigh_VBP the_DT risks_NNS associated_VBN with_IN the_DT medications_NNS )_) ._. But_CC for_IN the_DT
        subset_NN of_IN patients_NNS with_IN diabetes_NN and_CC preserved_VBN kidney_NN function_NN ,_, even_RB those_DT with_IN
        long-standing_JJ and_CC difficult-to-control_JJ disease_NN ,_, the_DT prognosis_NN for_IN survival_NN is_VBZ comparatively_RB
        much_RB better_JJR ._. In_IN addition_NN to_TO the_DT immunosuppressive_JJ toxicities_NNS ,_, other_JJ risks_NNS are_VBP associated_VBN
        with_IN the_DT islet_NN transplant_NN procedure_NN itself_PRP ,_, including_VBG intra-abdominal_JJ hemorrhage_NN following_VBG
        the_DT transplant_NN ,_, and_CC portal_NN vein_NN thromboses_NNS ._. The_DT fact_NN that_IN there_EX is_VBZ already_RB a_DT good_JJ
        alternative_NN to_TO islet_NN transplantation_NN (_( i_NNP ._. e_SYM ._. ,_, the_DT modern_JJ intensive_JJ insulin_NN regimen_NN )_) forces_NNS us_PRP
        to_TO regard_VB any_DT newer_JJR ,_, riskier_JJR interventions_NNS with_IN a_DT critical_JJ eye_NN ._.
        Like_IN all_DT transplantation_NN therapies_NNS ,_, islet_NN transplantation_NN is_VBZ also_RB handicapped_NNS by_IN the_DT
        limited_JJ donor_NN pool_NN ._. The_DT numbers_NNS are_VBP striking_JJ ;_: at_IN least_JJS 1_CD million_CD Americans_NNPS have_VBP T_NN 1_CD DM_NNP ,_, and_CC
        only_RB a_DT few_JJ thousand_CD donor_NN pancreata_NN are_VBP available_JJ each_DT year_NN ._. To_TO circumvent_VB this_DT organ_NN
        shortage_NN problem_NN ,_, researchers_NNS continue_VBP to_TO look_VB for_IN ways_NNS to_TO grow_VB islets—or_NN at_IN least_JJS cells_NNS
        capable_JJ of_IN physiologically_RB regulated_VBN insulin_NN secretion—in_NN vitro_NN ,_, but_CC currently_RB only_RB islets_NNS
        from_IN cadaveric_JJ donors_NNS can_MD be_VB used_VBN to_TO restore_VB euglycemia_NN ._. Further_RB exacerbating_VBG the_DT problem_NN
        (_( and_CC unlike_IN kidney_NN ,_, liver_NN ,_, and_CC heart_NN transplants_NNS ,_, where_WRB only_RB one_CD donor_NN is_VBZ needed_VBN for_IN each_DT
        recipient_JJ )_) most_JJS islet_NN transplant_NN patients_NNS require_VBP islets_NNS from_IN two_CD or_CC more_JJR donors_NNS to_TO achieve_VB
        euglycemia_NN ._. Lastly_NNP ,_, the_DT current_JJ methods_NNS for_IN islet_NN isolation_NN need_VBP improvement_NN ,_, since_IN only_RB
        about_IN half_NN of_IN attempted_VBD isolations_NNS produce_VBP transplant-ready_JJ islets_NNS ._.
        While_IN islet_NN transplantation_NN research_NN has_VBZ made_VBN important_JJ progress_NN and_CC the_DT success_NN stories_NNS
        are_VBP encouraging_VBG ,_, the_DT long-term_JJ safety_NN and_CC efficacy_NN of_IN the_DT procedure_NN remain_VB unclear_JJ ._. Other_JJ
        concerns_NNS relating_VBG to_TO the_DT field_NN include_VBP questions_NNS about_IN the_DT impact_NN of_IN having_VBG
        insulin-producing_JJ foreign_JJ cells_NNS within_IN the_DT hepatic_JJ parenchyma_NN ,_, the_DT long-term_JJ consequences_NNS
        of_IN elevated_JJ portal_NN pressures_NNS resulting_VBG from_IN the_DT islet_NN infusion_NN ,_, and_CC the_DT fact_NN that_IN islet_NN
        recipients_NNS can_MD be_VB sensitized_JJ against_IN donor_NN tissue_NN types_NNS ,_, making_VBG it_PRP more_RBR difficult_JJ to_TO find_VB a_DT
        suitable_JJ donor_NN should_MD another_DT life-saving_JJ transplant_NN be_VB required_VBN in_IN the_DT future_NN ._. Also_RB ,_, very_RB
        few_JJ islet_NN transplant_NN recipients_NNS have_VBP remained_VBN euglycemic_JJ without_IN the_DT use_NN of_IN any_DT exogenous_JJ
        insulin_NN beyond_IN four_CD years_NNS post-transplant_JJ ._. Thus_RB ,_, while_IN most_JJS islet_NN recipients_NNS achieve_VBP better_JJR
        glycemia_NN control_NN and_CC suffer_VB less_RBR serious_JJ hypoglycemia_NN ,_, islet_NN transplantation_NN continues_VBZ to_TO
        fall_VB short_JJ of_IN the_DT definitive_JJ diabetes_NN cure_NN ._.
      
      
        Is_VBZ Islet_NNP Transplantation_NNP Ready_JJ for_IN Widespread_NNP Use_NNP ?_.
        While_IN no_DT one_CD suggests_VBZ that_IN the_DT therapy_NN is_VBZ ready_JJ for_IN widespread_JJ clinical_JJ application_NN ,_,
        another_DT way_NN of_IN highlighting_VBG current_JJ problems_NNS is_VBZ to_TO focus_VB on_IN cost_NN ._. Assuming_VBG present_JJ hurdles_NNS
        were_VBD cleared_VBN ,_, islet_NN transplantation_NN costs_NNS approximately_RB $_$ 150_CD ,_, 000_CD per_IN patient_NN per_IN
        transplant_NN ._. With_IN over_IN 1_CD million_CD Americans_NNPS dealing_VBG with_IN T_NN 1_CD DM_NNP ,_, it_PRP would_MD cost_VB over_IN $_$ 100_CD
        billion_CD to_TO give_VB each_DT patient_NN a_DT single_JJ islet_NN transplant_NN ,_, with_IN little_JJ assurance_NN as_RB yet_RB of_IN any_DT
        long-term_JJ benefit_NN ._. In_IN contrast_NN ,_, the_DT annual_JJ direct_JJ cost_NN of_IN a_DT proven_VBN therapy_NN like_IN intensive_JJ
        insulin_NN treatment_NN is_VBZ about_IN $_$ 3_CD ,_, 500_CD per_IN patient_NN [_NN 17_CD ]_NN ._.
        The_DT limitations_NNS of_IN islet_NN transplantation_NN force_NN us_PRP to_TO recognize_VB that_IN the_DT therapy_NN remains_VBZ
        experimental_JJ ,_, and_CC that_IN many_JJ questions_NNS must_MD be_VB answered_VBN before_IN it_PRP is_VBZ incorporated_VBN into_IN
        general_JJ clinical_JJ practice_NN ._. At_IN the_DT present_JJ time_NN ,_, we_PRP urge_VBP a_DT focus_NN on_IN the_DT selection_NN of_IN only_RB
        those_DT patients_NNS for_IN whom_WP this_DT procedure_NN offers_VBZ the_DT greatest_JJS likelihood_NN of_IN benefit_NN ._. Most_JJS
        people_NNS with_IN diabetes_NN can_MD ,_, with_IN diligence_NN and_CC perseverance_NN ,_, implement_VB an_DT insulin_NN regimen_NN
        that_WDT maintains_VBZ tight_JJ glucose_NN control_NN while_IN avoiding_VBG dangerous_JJ hypoglycemia_NN ._. However_RB ,_, there_EX
        are_VBP some_DT patients_NNS who_WP continue_VBP to_TO have_VB tremendous_JJ difficulty_NN managing_VBG their_PRP$ disease_NN despite_IN
        optimal_NN care_NN and_CC effort_NN ._. Even_RB the_DT statement_NN “ despite_IN optimal_NN care_NN and_CC effort_NN” is_VBZ difficult_JJ
        to_TO define_VB ,_, and_CC we_PRP advocate_VBP that_IN all_DT patients_NNS being_VBG considered_VBN for_IN an_DT islet_NN transplant_NN first_RB
        be_VB referred_VBN for_IN several_JJ months_NNS to_TO specialty_NN teams_NNS that_WDT are_VBP committed_VBN to_TO diabetes_NN care_NN ._.
        Since_IN such_JJ patients_NNS whose_WP$ diabetes_NN is_VBZ the_DT most_RBS difficult_JJ to_TO control_VB have_VBP a_DT poor_JJ quality_NN of_IN
        life_NN ,_, islet_NN transplantation_NN offers_VBZ potential_JJ benefit_NN ._. Even_RB a_DT low_JJ baseline_NN level_NN of_IN insulin_NN
        production_NN by_IN the_DT transplanted_VBN islets_NNS may_MD lower_VB the_DT amount_NN of_IN insulin_NN required_VBD ,_, while_IN
        reducing_VBG the_DT number_NN and_CC severity_NN of_IN hypoglycemic_JJ events_NNS ._. We_PRP also_RB believe_VBP the_DT islet_NN
        transplant_NN risk-benefit_JJ ratio_NN is_VBZ favorable_JJ for_IN those_DT with_IN both_DT T_NN 1_CD DM_NNP and_CC kidney_NN failure_NN who_WP
        are_VBP listed_VBN for_IN a_DT life-preserving_JJ kidney_NN transplant_NN ;_: such_JJ patients_NNS will_MD have_VB to_TO take_VB
        immunosuppressive_JJ agents_NNS after_IN transplant_NN to_TO preserve_VB the_DT kidney_NN allograft_NN function_NN ,_, so_IN the_DT
        islets_NNS can_MD be_VB added_VBN without_IN too_RB much_JJ additional_JJ risk_NN ._.
        Where_WRB do_VBP we_PRP go_VBP from_IN here_RB ?_. Just_RB as_IN early_JJ studies_NNS showed_VBD islet_NN transplantation_NN 's_POS promise_NN ,_,
        research_NN must_MD now_RB overcome_VB the_DT hurdles_NNS revealed_VBN by_IN the_DT recent_JJ islet_NN transplant_NN experience_NN ._.
        New_JJ immunomodulatory_NN agents_NNS offer_VBP the_DT greatest_JJS hope_VBP of_IN revolutionizing_VBG the_DT field_NN ._. New_JJ drug_NN
        regimens_NNS capable_JJ of_IN inducing_VBG tolerance_NN to_TO the_DT transplanted_VBN islets_NNS would_MD allow_VB recipients_NNS to_TO
        maintain_VB their_PRP$ grafts_NNS without_IN general_JJ immunosuppression_NN and_CC its_PRP$ associated_VBN toxicities_NNS ._.
        While_IN many_JJ targets_NNS are_VBP currently_RB under_IN investigation_NN ,_, none_NN are_VBP ready_JJ for_IN clinical_JJ use_NN ._. We_PRP
        advocate_VBP that_IN such_JJ immunomodulatory_NN approaches_NNS be_VB tested_VBN first_JJ in_IN controlled_VBN models_NNS where_WRB
        the_DT results_NNS can_MD be_VB appropriately_RB attributed_VBN to_TO the_DT agent_NN itself_PRP ._.
      
      
        Conclusion_NNP
        Less_RBR than_IN a_DT century_NN ago_RB ,_, T_NN 1_CD DM_NNP was_VBD invariably_RB a_DT fatal_JJ disease_NN ._. With_IN the_DT advent_NN of_IN
        insulin_NN ,_, the_DT prognosis_NN changed_VBD overnight_JJ ,_, and_CC we_PRP have_VBP continued_VBN to_TO witness_NN improvements_NNS in_IN
        diabetes_NN care_NN and_CC outcomes_NNS ._. Pancreatic_NNP islet_NN transplant_NN has_VBZ offered_VBN renewed_VBN hope_VBP to_TO many_JJ
        patients_NNS with_IN diabetes_NN ,_, who_WP envision_VBP a_DT life_NN free_JJ of_IN glucose_NN checks_NNS and_CC insulin_NN injections_NNS ._.
        Some_DT transplanted_VBN patients_NNS have_VBP enjoyed_VBN “ success_NN” and_CC are_VBP pleased_VBN with_IN their_PRP$ decisions_NNS ;_:
        unfortunately_RB these_DT results_NNS are_VBP not_RB universal_JJ ._. Researchers_NNS must_MD continue_VB to_TO look_VB for_IN ways_NNS
        to_TO improve_VB the_DT procedure_NN while_IN protecting_VBG the_DT welfare_NN of_IN each_DT individual_JJ patient_NN ._. The_DT field_NN
        has_VBZ come_VBN a_DT long_JJ way_NN ,_, but_CC we_PRP must_MD remain_VB cautious_JJ ,_, as_IN we_PRP are_VBP treating_VBG a_DT non-fatal_JJ disease_NN
        for_IN which_WDT there_EX is_VBZ a_DT very_RB effective_JJ standard_JJ therapy_NN ._.
      
    
  
